Familial mediterranean fever – Diagnostics – Overview of Information and Clinical Research

Familial Mediterranean fever is a genetic condition that causes recurring episodes of fever and pain throughout the body, particularly affecting people of Mediterranean and Middle Eastern descent. Understanding how this condition is diagnosed—from recognizing early warning signs to undergoing specialized tests—can make the difference between years of uncertainty and proper management that prevents serious complications.

Introduction: Who Should Undergo Diagnostics

If you experience repeated episodes of fever accompanied by sudden, severe pain in your belly, chest, or joints, it may be time to seek diagnostic testing for Familial Mediterranean fever. These attacks are not random infections or flu symptoms—they follow a distinct pattern that doctors can recognize and diagnose. The condition typically reveals itself during childhood, with roughly 90% of cases beginning before age 20, and about 75% starting before age 10. However, some people experience their first attack much later in life, which can make diagnosis more challenging.^[1]^[2]

People who should consider seeking diagnostics include those of Mediterranean or Middle Eastern ancestry who experience unexplained recurring fevers. This includes individuals of Armenian, Arab, Turkish, Jewish, Greek, Italian, Kurdish, or Iranian heritage. If you come from one of these ethnic backgrounds and have family members with similar symptoms, diagnostic testing becomes even more important. The condition runs in families because it is inherited, meaning it passes from parents to children through genes.^[3]^[6]

Parents should seek diagnostic evaluation if their child experiences repeated fevers that seem to have no clear cause, especially when accompanied by severe belly pain that might be mistaken for appendicitis (inflammation of the appendix requiring emergency surgery). Some children under five may only show fever without other obvious symptoms, making diagnosis particularly tricky. The attacks typically develop over a few hours and last anywhere from 12 hours to three days. Between episodes, children usually feel completely normal, which can be confusing for both families and healthcare providers.^[7]^[12]

It is advisable to seek medical attention promptly if fever appears alongside multiple symptoms such as abdominal distention (swelling), rigid stomach muscles, chest pain that worsens when breathing deeply, or swollen joints. Women who notice their attacks coincide with their menstrual cycle or ovulation should also mention this pattern to their doctor, as it can be an important diagnostic clue. Some people experience warning signs—called prodromal symptoms—in the days before an attack begins. These may include unexplained anxiety, irritability, headache, nausea, body aches, or general feelings of discomfort.^[3]^[11]

⚠️ Important

Without early diagnosis and proper treatment, Familial Mediterranean fever can lead to a dangerous complication called amyloidosis, where abnormal proteins build up in organs, especially the kidneys. This can eventually cause kidney failure. In some patients, amyloidosis might even be the first sign that leads to the diagnosis of Familial Mediterranean fever. Early diagnostic testing and treatment can prevent this serious outcome.

Classic Diagnostic Methods

Diagnosing Familial Mediterranean fever requires a combination of approaches because there is no single definitive test that works in all cases. Doctors begin with a thorough physical examination and a detailed conversation about your symptoms and their pattern. They will ask specific questions about when attacks occur, how long they last, what symptoms you experience, and whether you feel completely normal between episodes. Understanding your family’s medical history is particularly crucial—if relatives have experienced similar symptoms or have been diagnosed with the condition, this strengthens the diagnostic picture.^[8]^[13]

Blood tests play a central role in diagnosis, but timing matters significantly. During an attack, blood tests reveal elevated levels of certain markers that indicate inflammation is occurring in your body. One important marker is an increased number of white blood cells, which are the cells your body uses to fight infections and respond to inflammation. Other inflammatory markers may also be elevated. However, these tests alone cannot confirm Familial Mediterranean fever because many other conditions can cause similar changes. Between attacks, when you feel well, these blood markers typically return to normal levels, which itself can be a diagnostic clue.^[8]

Urine tests are also performed, particularly to check for protein in the urine, which could indicate amyloidosis—the buildup of abnormal protein deposits in organs. This complication affects the kidneys most severely and can occur even without obvious attack symptoms. For this reason, people with suspected or confirmed Familial Mediterranean fever should have their urine checked regularly, typically every six months, even if they have mild symptoms and are not receiving treatment.^[13]^[18]

Genetic testing represents a major advancement in diagnosing Familial Mediterranean fever, though it has important limitations. The test looks for changes (called mutations or variants) in a specific gene called MEFV, which is located on chromosome 16. This gene provides instructions for making a protein called pyrin, which helps regulate inflammation in the body. When the MEFV gene contains certain mutations, the pyrin protein does not work properly, leading to uncontrolled inflammation and the symptoms of Familial Mediterranean fever.^[2]^[6]

Scientists have identified around 300 different mutations in the MEFV gene that can cause the condition. Five of these mutations—V726A, M680I, E148Q, M694V, and M694I—account for approximately 70 to 80 percent of all cases. However, genetic testing is not perfect. About 10 percent of people who clearly have Familial Mediterranean fever based on their symptoms show no mutations in genetic testing. This happens because current tests cannot detect all possible mutations, or there may be genetic changes in parts of the gene that the test does not examine.^[2]^[9]

Because genetic testing can produce false-negative results (showing no mutation when one actually exists), healthcare providers typically do not rely on genetic testing alone to make a diagnosis. Instead, they use it to confirm a diagnosis that is already suspected based on symptoms, family history, ethnic background, and other test results. A positive genetic test strongly supports the diagnosis, but a negative test does not rule it out if the clinical picture suggests Familial Mediterranean fever.^[8]

Doctors often use established diagnostic criteria to help determine whether someone has Familial Mediterranean fever. The most widely recognized are the Tel-Hashomer criteria, which have more than 95 percent sensitivity and 97 percent specificity. These criteria define what counts as a typical attack: the episodes must be recurrent (occurring three or more times), accompanied by fever (rectal temperature of at least 38°C or about 100.4°F), cause painful inflammation, and last between 12 and 72 hours. The criteria also account for incomplete attacks that differ in at least one feature—for example, fever might be lower than specified, or the attack might last slightly longer or shorter than usual but still between six hours and seven days.^[5]

Distinguishing Familial Mediterranean fever from other conditions is an essential part of diagnosis. The severe abdominal pain can mimic surgical emergencies like appendicitis or perforated ulcers, sometimes leading to unnecessary operations. Chest pain from inflammation of the lining around the lungs (called pleuritis) can be confused with heart problems or pneumonia. Joint pain affecting a single large joint like the knee or ankle might suggest arthritis or injury. Doctors must carefully consider these possibilities and rule out other causes of recurring fever, including infections, other periodic fever syndromes, and autoimmune diseases.^[1]^[5]

Diagnostics for Clinical Trial Qualification

When patients are considered for participation in clinical trials testing new treatments for Familial Mediterranean fever, specific diagnostic tests serve as standard criteria for enrollment. These trials typically require confirmed diagnosis through a combination of methods to ensure that participants truly have the condition and that results will be meaningful. The exact requirements vary depending on the specific trial, but certain diagnostic elements appear consistently across studies.^[8]

Genetic testing usually plays a prominent role in qualifying patients for clinical trials. Many trials require documentation of at least one mutation in the MEFV gene, with some requiring two mutations (one from each parent, which is the typical inheritance pattern). Trials may specify which mutations are acceptable for enrollment or require that mutations fall within certain exons (sections) of the gene, particularly exons 2, 3, 5, and 10, where disease-causing mutations commonly occur. This genetic confirmation helps ensure that trial participants have the specific biological mechanism that researchers are trying to target with the treatment being tested.^[2]

Clinical trials typically require detailed documentation of attack frequency and characteristics over a defined period before enrollment, often several months. Patients may need to maintain a diary recording each attack, its duration, which symptoms occurred, and how severe they were. This baseline information allows researchers to determine whether a new treatment actually reduces attacks compared to what patients were experiencing beforehand. Trials may set minimum or maximum attack frequencies for enrollment—for example, requiring that patients experience at least a certain number of attacks per month but are not experiencing attacks so frequently that they never fully recover between episodes.^[10]

Blood tests documenting elevated inflammatory markers during attacks may be required as objective evidence that true inflammatory episodes are occurring. Some trials specifically measure inflammatory proteins such as C-reactive protein or serum amyloid A, which rise dramatically during attacks in people with Familial Mediterranean fever. Normal levels of these markers between attacks, with documented elevation during attacks, provides strong objective evidence supporting the diagnosis.^[2]

For trials testing treatments in patients who have not responded well to standard therapy with colchicine (the first-line medication), documentation of inadequate response or intolerance is essential. This might include medical records showing that despite taking appropriate doses of colchicine, attacks continued at an unacceptable frequency or severity. Alternatively, documentation that the patient experienced side effects from colchicine that prevented them from taking an effective dose may qualify them for trials of alternative treatments. Blood or urine tests may be used to confirm that patients were actually taking colchicine as prescribed by measuring drug levels in the body.^[8]^[10]

Assessment for amyloidosis is another important diagnostic element in many clinical trials. Researchers may perform kidney function tests, including blood tests measuring creatinine levels and urine tests checking for protein, to determine whether kidney damage from amyloid deposits has occurred. Some trials specifically enroll patients with or without amyloidosis, while others may exclude patients whose kidney disease has progressed beyond a certain point. Understanding the presence and extent of organ damage helps researchers evaluate whether treatments might prevent or slow this serious complication.^[2]

Imaging studies or other specialized tests may be required in some trials, depending on what the researchers are investigating. For example, if a trial focuses on joint complications of Familial Mediterranean fever, detailed assessment of joint structure and function might be needed before enrollment. Trials examining inflammation of the lining around the heart might require specialized heart imaging or testing. These additional diagnostic procedures ensure that researchers can accurately measure whether the treatment affects specific aspects of the disease.^[8]

Prognosis and Survival Rate

Prognosis

The prognosis for people with Familial Mediterranean fever has improved dramatically with early diagnosis and proper treatment. When patients take colchicine as prescribed from an early age, most can lead completely normal, productive lives with minimal impact from the disease. The medication prevents or significantly reduces attack frequency in more than 90 percent of patients and, most importantly, prevents the development of amyloidosis—the most serious and potentially fatal complication of the condition.^[4]^[12]

Several factors influence the prognosis for individual patients. Ethnicity plays a role, with certain populations facing higher risk of complications. For example, people of North African Jewish, Turkish, and Armenian ancestry living in Armenia appear to be at particularly high risk of developing amyloidosis if untreated, making daily colchicine therapy essential. In contrast, Ashkenazi Jewish people and Armenian people living in the United States seem to face extremely low risk of amyloidosis and may sometimes manage with intermittent treatment targeted at preventing individual attacks.^[10]

The specific genetic mutations a person carries also affect prognosis. Some mutations, particularly M694V, are associated with more severe disease, earlier onset, and higher risk of amyloidosis. Patients with two mutations (one from each parent) generally experience more severe disease than those with a single mutation. However, about one-third of patients have only one detectable mutation, yet still develop the full disease, suggesting that factors beyond genetics contribute to how the condition progresses.^[6]

Without treatment, the outlook is considerably more concerning. Untreated or inadequately treated Familial Mediterranean fever can lead to amyloidosis in a significant percentage of patients, particularly those from high-risk ethnic groups. Once amyloidosis develops in the kidneys, it can progress to kidney failure, requiring dialysis or kidney transplant. However, colchicine can stabilize protein levels in the urine in patients who already have kidney involvement, and kidney disease may even improve in patients whose creatinine levels are still relatively normal when treatment begins.^[2]^[10]

The pattern of attacks often changes over a patient’s lifetime. Symptoms are frequently most severe during childhood and adolescence, then become less frequent and less intense with advancing age. Between attacks, patients typically feel completely healthy, allowing them to pursue education, careers, relationships, and physical activities without limitation. Children who experience frequent attacks may face challenges with growth and recovery, but with proper treatment, these issues can be avoided.^[3]^[7]

For the small percentage of patients who do not respond adequately to colchicine or cannot tolerate it due to side effects, newer medications that block inflammatory signals in the body offer good alternatives. These drugs, including anakinra, canakinumab, and rilonacept, have shown effectiveness in controlling attacks and preventing complications, giving these patients similarly positive outlooks. With regular treatment and monitoring, even patients with difficult-to-control disease can live normal lifespans.^[7]^[10]

Survival rate

Specific survival rate statistics for Familial Mediterranean fever are not prominently reported in medical literature, largely because with appropriate treatment, the condition does not significantly affect lifespan. When patients receive early diagnosis and maintain consistent treatment with colchicine or alternative medications, they can expect normal life expectancy. The disease itself, when properly managed, does not increase mortality risk.^[12]^[16]

The primary threat to survival comes from untreated or inadequately treated disease leading to kidney failure from amyloidosis. Before colchicine became standard treatment, amyloidosis was a common and often fatal complication. However, since the introduction of colchicine therapy in the 1970s and its widespread adoption, this complication has become largely preventable. Patients who develop colchicine therapy before amyloidosis occurs essentially eliminate this risk entirely.^[2]

Even in cases where amyloidosis has already developed, modern medical interventions including continued colchicine therapy, management of kidney disease, dialysis when necessary, and kidney transplantation have dramatically improved outcomes. Patients who receive kidney transplants for amyloidosis-related kidney failure can have good long-term survival, though they must continue colchicine therapy to prevent amyloid deposits from forming in the transplanted kidney.^[2]

Children diagnosed early and treated consistently from childhood can expect to grow normally, attend school regularly, participate in sports and activities, pursue higher education, and lead productive adult lives without shortened lifespan. The key to this excellent outcome is taking medication as prescribed without skipping doses, attending regular medical appointments for monitoring, and promptly reporting any changes in symptoms or new concerns to healthcare providers.^[7]^[12]

#1 Clinical Trials Search in Europe